BioLife Solutions (BLFS) CMO sells 344 shares under 10b5-1 plan

Rhea-AI Filing Summary

BioLife Solutions' Chief Marketing Officer reported a small insider sale of company stock. On 01/06/2026, Todd Berard sold 344 shares of BioLife Solutions common stock at a price of $25.59 per share, leaving him with 132,564 shares beneficially owned directly after the transaction.

According to the disclosure, this sale was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 and was executed to satisfy tax withholding obligations related to the vesting of restricted stock. This indicates the transaction was part of tax and compensation administration rather than a discretionary open-market sale.

Insider Trade Summary

Net Seller: 344 shares ($8,803)

Net Sell 1 txn

Insider Berard Todd

Role Chief Marketing Officer

Sold 344 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock	344	$25.59	$9K

Holdings After Transaction: Common Stock — 132,564 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		344	D	$25.59	132,564	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Todd Berard	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLife Solutions (BLFS) report in this Form 4?

The filing reports that Chief Marketing Officer Todd Berard sold 344 shares of BioLife Solutions common stock on 01/06/2026 at $25.59 per share.

How many BioLife Solutions (BLFS) shares does the CMO hold after the reported sale?

Following the reported transaction, Todd Berard beneficially owns 132,564 shares of BioLife Solutions common stock in direct ownership.

Was the BioLife Solutions CMO’s stock sale made under a Rule 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1(c) trading plan adopted by the reporting person and effective as of 01-03-2023.

Why did the BioLife Solutions CMO sell 344 shares of BLFS stock?

The filing states the sale was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

What role does the reporting person hold at BioLife Solutions (BLFS)?

The reporting person, Berard Todd, is an officer of BioLife Solutions, serving as Chief Marketing Officer.

Is this BioLife Solutions Form 4 filed for one or multiple reporting persons?

This Form 4 is filed by one reporting person, identified as Chief Marketing Officer Todd Berard.